Core Viewpoint - Datacentrex, Inc. has successfully closed a public offering, raising gross proceeds of $20.17 million through the sale of 4,510,000 shares of common stock and 5,757,000 pre-funded warrants at a price of $2.00 per share [1][2]. Group 1: Offering Details - The public offering included 4,510,000 shares of common stock and 5,757,000 pre-funded warrants, resulting in gross proceeds of $20.17 million before expenses [1]. - The net proceeds from the offering will be utilized for working capital and general corporate purposes [2]. - Dominari Securities LLC served as the exclusive placement agent for the offering [2]. Group 2: Regulatory Information - The offering was conducted under an effective shelf registration statement on Form S-3, initially filed with the SEC on May 2, 2025, and declared effective on May 30, 2025 [2]. - A preliminary prospectus supplement was filed with the SEC on March 26, 2026, and a final prospectus supplement was filed on March 30, 2026, both available on the SEC's website [3]. Group 3: Company Overview - Datacentrex is a digital infrastructure and capital deployment company that operates Scrypt compute assets and evaluates strategic transactions across asset-backed operating businesses [5]. - The company's operations focus on Scrypt-based proof-of-work compute deployed through third-party colocation facilities, monetizing this compute primarily through hashrate marketplace mechanisms [5].

Core Viewpoint - InspireMD, Inc. is set to present at the 25th Annual Needham Virtual Healthcare Conference, highlighting its focus on the CGuard Prime carotid stent system aimed at stroke prevention [1]. Company Overview - InspireMD, Inc. utilizes proprietary MicroNet™ mesh technology to establish its products as the industry standard for carotid stenting, aiming for excellent acute results and long-term stroke-free outcomes [2]. - The company's common stock is traded on Nasdaq under the ticker symbol NSPR, and it regularly updates important information for investors on its website [2].

Core Insights - Femasys Inc. has made significant progress in clinical, regulatory, and commercial milestones for its FemBloc and FemaSeed products, with ongoing enrollment in the pivotal FINALE clinical trial for FemBloc aimed at U.S. FDA approval [3][5] - The company reported a 40.8% increase in sales for 2025, primarily driven by FemBloc, and has sufficient cash to fund operations into the third quarter of 2026 [6][7] Corporate Highlights - Initiated patient enrollment in the FINALE pivotal clinical trial for FemBloc, a key step toward U.S. approval [5] - Expanded FemaSeed commercialization in the U.S. with the introduction of the FemSperm product family [3] - Appointed Kenneth D. Eichenbaum, M.D., M.S.E., to the Board of Directors to strengthen leadership [5] - Achieved certification for FemBloc under the Medical Device Single Audit Program (MDSAP) [5] - Received approval for a new Category III CPT code for FemaSeed, supporting future reimbursement pathways [5] - Entered a strategic distribution partnership with OR Consulting for product launches in Switzerland [5] - Established a partnership with Refuah Health Center to advance FemaSeed adoption in community-based care [5] - Secured FDA 510(k) clearance for the FemVue Controlled device [5] - Completed $12 million financing to strengthen the balance sheet [5] - Initiated a European post-market surveillance study for FemBloc [5] Financial Results - Sales increased by $664,205 to $2,293,313 in 2025 from $1,629,108 in 2024 [6] - Research and development expenses decreased by $638,839 to $7,577,704 in 2025 compared to $8,216,543 in 2024 [6] - Net loss for 2025 was $18,627,887, or ($0.47) per share, compared to a net loss of $18,816,628, or ($0.85) per share in 2024 [6][15] - Cash and cash equivalents as of December 31, 2025, were approximately $9.3 million, with an accumulated deficit of approximately $145.8 million [6][7] Product and Market Information - FemBloc is the first non-surgical, in-office alternative to surgical sterilization, receiving full regulatory approval in Europe, the UK, and New Zealand in 2025 [17] - FemaSeed is a first-line infertility treatment that has demonstrated more than double the pregnancy rate of traditional IUI [16][17] - The FemSperm product line enables in-office sperm preparation and analysis for infertility treatment [3][16]

Core Insights - Fortress Biotech, Inc. has achieved significant milestones in 2025 and early 2026, including the FDA approval of ZYCUBO for Menkes disease and the sale of a Rare Pediatric Disease Priority Review Voucher for $205 million, demonstrating the company's ability to monetize its assets and advance its portfolio [2][5][12] Regulatory Updates - ZYCUBO (copper histidinate) received FDA approval in January 2026 for treating Menkes disease in pediatric patients [5] - The approval was followed by the sale of the Rare Pediatric Disease Priority Review Voucher by Cyprium Therapeutics for gross proceeds of $205 million [5] Monetization Updates - Checkpoint Therapeutics was acquired by Sun Pharma for approximately $355 million, with Fortress receiving about $28 million upfront and potential future payments including a 2.5% royalty on net sales of UNLOXCYT™ [4][6] - Fortress expects to receive at least $100 million from Cyprium through future dividends and intercompany agreements [5] Financial Performance - Fortress reported consolidated net revenue of $63.3 million for the full year ended December 31, 2025, an increase from $57.7 million in 2024 [12][20] - The company incurred a consolidated net loss attributable to common stockholders of $(1.9) million, or $(0.07) per share, for 2025, compared to a net loss of $(55.9) million, or $(2.69) per share, in 2024 [12][20] Clinical Updates - Crystalys Therapeutics announced a $205 million Series A financing to support Phase 3 clinical studies for dotinurad, with Fortress holding a 3% royalty on future net sales [9][10] - Emrosi™, developed by Journey Medical, reported net product revenues of $61.2 million for 2025, up from $55.1 million in 2024 [7][12]

Core Insights - The funding round totals $122 billion and includes major players such as Amazon, Nvidia, SoftBank, and wealthy investors [1] - A money manager involved in this round plans to incorporate the startup into its exchange-traded funds [1] Company Involvement - Amazon is one of the key investors in the $122 billion funding round [1] - Nvidia's participation highlights its interest in emerging technologies and startups [1] - SoftBank continues to be a significant player in the investment landscape with its involvement in this funding round [1] Investment Trends - The substantial amount raised indicates a strong interest in the startup sector from both institutional and wealthy individual investors [1] - The inclusion of the startup in exchange-traded funds suggests a growing trend of integrating innovative companies into mainstream investment vehicles [1]

Exceeds All Financial Guidance MetricsACV as of January 31, 2026, $602.4M, up 17% Year-Over-YearFiscal 2026 ACV Net Retention Rate of 112%Announces $100M Accelerated Share Repurchase Program WILMINGTON, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- nCino, Inc. (NASDAQ: NCNO), the leading provider of intelligent, best-in-class banking solutions, today announced financial results for the fourth quarter and fiscal year 2026, ended January 31, 2026. “Fiscal 2026 was a landmark year for nCino, with both the fourth qu ...

Group 1 - The 2026 Annual Shareholder Meeting of Howard Hughes Holdings (HHH) will be held on September 17, 2026, in New York City, instead of June as originally planned [1][2] - Executive Chairman Bill Ackman and Chief Investment Officer Ryan Israel will present on the acquisition of Vantage Group Holdings, which is expected to close in Q2 2026 [1][2] - The meeting will include a Q&A session with CEO David O'Reilly, and is open to the public with advance registration required, prioritizing HHH stockholders [2] Group 2 - Bill Ackman emphasized that the acquisition of Vantage will combine its insurance expertise with Pershing Square's investment capabilities, aiming to create a large, profitable insurance company and long-term value for shareholders [2] - Howard Hughes Holdings focuses on growing long-term shareholder value through its real estate platform, owning and managing various commercial, residential, and mixed-use properties across the U.S. [3]

Industry Overview - The global wind power market in 2025 is projected to have new installations of 169.2 gigawatts, representing a 37.9% increase compared to previous years [3] - Onshore wind power installations are expected to reach 161 gigawatts, up by 45.1%, while offshore installations will total 8.1 gigawatts, reflecting a decline of 30.2% [3] - China continues to lead in global wind power installations, contributing three-quarters of the total new capacity in 2025 [4] Company Performance - In 2025, China's grid connection capacity for wind power is anticipated to be 120 gigawatts, with 113 gigawatts from onshore and 6.59 gigawatts from offshore sources [4] - By the end of 2025, China's cumulative grid connection capacity will reach 640 gigawatts, accounting for 16.4% of the total power mix, while thermal power will decrease to 39.6% [5] - Electricity production in China for the previous year was 10,368.2 billion kilowatt hours, marking a 5.0% year-on-year increase [5]

MONTREAL, March 31, 2026 (GLOBE NEWSWIRE) -- Senvest Capital Inc. today reported net income attributable to common shareholders of $149.3 million or $61.40 per share for the year ended December 31, 2025. This compares to a net income attributable to common shareholders of $258.1 million or 105.06 per share for the same period in 2024 Financial statements are available online at Sedar+ www.sedarplus.ca CONSOLIDATED STATEMENTS OF INCOME (unaudited) (in millions of dollars, except per share amounts) For the ...

Core Insights - Rail Vision Ltd. reported a transformative year in 2025, achieving significant revenue growth and operational advancements in the railway safety technology sector, driven by AI-integrated sensing systems [2][3]. Financial Performance - Revenue for the year ended December 31, 2025, increased by 14.4% to $1,487,000, compared to $1,300,000 in 2024, primarily due to additional installations and orders [8]. - The operating loss for 2025 was $11,735,000, compared to a loss of $9,004,000 in 2024, reflecting increased research and development expenses [13]. - GAAP net loss for 2025 was $11,100,000, or $6.15 per share, a significant improvement from a net loss of $30,708,000, or $55.41 per share, in 2024 [13][33]. - Cash and cash equivalents totaled approximately $20 million as of December 31, 2025, with zero financial debt [11][13]. Business Developments - Rail Vision advanced key installations with Israel Railways and secured follow-on orders from a leading mining operator in Latin America, demonstrating the commercial validation of its technology [3][5]. - The company signed a Memorandum of Understanding with Sujan Industries in India, successfully completing a proof of concept for its MainLine system [6]. - Rail Vision acquired a 51% stake in Quantum Transportation, enhancing its capabilities in quantum computing applications for railway safety [7]. Market Context - The global railroad industry was valued at over $340 billion in 2025 and is projected to grow toward $460 billion by the mid-2030s, providing a favorable environment for Rail Vision's growth [3].